Who are Survanta's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Curosurf, Infasurf, Colace, Lung lavage with surfactant, Poractant alfa instillation, Budesonide-Surfactant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/beractant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Survanta — Competitive Intelligence Brief

Survanta (BERACTANT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Surfactant [EPC]. Area: Respiratory.

marketed Surfactant [EPC] Respiratory Live · refreshed every 30 min

Target snapshot

Survanta (BERACTANT) — AbbVie.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Survanta TARGET	BERACTANT	AbbVie	marketed	Surfactant [EPC]		1991-01-01
Curosurf	PORACTANT ALFA	Chiesi Usa Inc	marketed	Surfactant [EPC]		1999-01-01
Infasurf	CALFACTANT	ONY	marketed	Surfactant [EPC]		1998-01-01
Colace	docusate sodium	Generic (multiple manufacturers)	marketed	Stool softener (surfactant laxative)	N/A (surfactant mechanism)	1955-01-01
Lung lavage with surfactant	Lung lavage with surfactant	Zekai Tahir Burak Women's Health Research and Education Hospital	marketed	Therapeutic procedure with surfactant replacement
Poractant alfa instillation	Poractant alfa instillation	Poznan University of Medical Sciences	marketed	Pulmonary surfactant replacement	Pulmonary surfactant (lipid and protein complex)
Budesonide-Surfactant	Budesonide-Surfactant	China Medical University Hospital	marketed	Inhaled corticosteroid with surfactant excipient	Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Surfactant [EPC] class)

AbbVie · 1 drug in this class
Chiesi Usa Inc · 1 drug in this class
ONY · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Survanta — Competitive Intelligence Brief. https://druglandscape.com/ci/beractant. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab